Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lenti-PROST-02
- Development stage
- Preclinical
- Lead developer
- Theravectys
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intramuscular
01
Overview
Lenti-PROST-02 is a preclinical-stage therapeutic cancer vaccine developed by Theravectys for the treatment of prostate cancer. It is a non-integrative lentiviral vector-based immunotherapy designed to encode clusters of T-cell immunodominant regions of human prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA). By directly targeting and transducing dendritic cells, Lenti-PROST-02 triggers a potent, long-lasting cellular immune response, inducing poly-functional CD8+ T-cell effectors and remodeling the tumor microenvironment from 'cold' to 'hot' to eradicate prostate tumors and prevent relapse.
02
Targets
MHC I (MHC class I})γδ TCR (T-cell receptor)PSA (Puromycin-sensitive aminopeptidase)PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on Lenti-PROST-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lenti-PROST-02.